Shares in Novartis AG reflect an interesting technical chart pattern allowing for a bet on a reversal of the medium term trend. Investors have an opportunity to buy the stock and target the CHF 80.
For a short-term investment strategy, the company has poor fundamentals.
The share is getting closer to its long-term support in weekly data, at CHF 68.5, which offers good timing for buyers.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is one of the best yield companies with high dividend expectations.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
According to forecast, a sluggish sales growth is expected for the next fiscal years.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
The company's enterprise value to sales, at 3.96 times its current sales, is high.
For the past seven days, analysts have been lowering their EPS expectations for the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.